---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-025048"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:38:03.343868+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SELLAS Life Sciences prices $20M public offering of common stock and warrants

## Summary
- 7,220,217 shares and warrants at $2.77/unit; gross proceeds $20M.
- Net proceeds ~$18.5M after underwriting discounts and offering expenses.
- Warrants exercisable at $2.77/share, immediately exercisable, expire in 5 years.
- Company reduces exercise price of 3,438,851 existing warrants to $3.62.
- Offering expected to close on February 28, 2023, subject to customary conditions.

## SEC filing metadata
- accession: 0001104659-23-025048
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465923025048/0001104659-23-025048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465923025048/tm237769d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-025048
- JSON: https://secwatch.observer/filing/0001104659-23-025048.json
- Plain text: https://secwatch.observer/filing/0001104659-23-025048.txt

## Key facts
- Material Agreements
  SELLAS Life Sciences Group, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at approximately $18.5 million (effective 2023-02-23).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: approximately $18.5 million
  - Effective: 2023-02-23
  source text: On February 23, 2023, SELLAS Life Sciences Group, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Cantor Fitzgerald & Co., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), relating to an underwritten public offering of 7,220,217 shares (the “ Underwritten Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and warrants (the “ Warrants ”, and together with the Underwritten Shares, the “ Securities ”) to purchase up to 7,220,217 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000110465923025048/0001104659-23-025048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.